Auto‐abs against IFN‐α2, IFN‐β, and/or IFN‐ω in hospitalized patients with MERS
MERS
MIDDLE EAST RESPIRATORY SYNDROME
Among the 62 enrolled patients with laboratory‐confirmed MERS, 15 patients (24.2%) were positive for immunoglobulin G auto‐Abs for at least one subtype of type I IFNs, including IFN‐α2, IFN‐β, and/or IFN‐ω (Figure Multiplex particle‐based assay for autoantibodies (auto‐Abs) against interferon (IFN)‐α2, IFN‐β, and IFN‐ω in hospitalized patients with Middle East respiratory syndrome (MERS) ((A) Distribution of the number of positive samples for patients with immunoglobulin G autoantibodies (auto‐Abs) for more than one subtype of type I interferons (IFNs) (IFN‐α2, IFN‐ω, and IFN‐β) and (IFN‐α2 and IFN‐ω) and patients with immunoglobulin G auto‐Abs for only one subtype of type I IFNs. (B) Distribution of auto‐Ab titers of patients with positive auto‐Abs samples and mortality.